BR9712023A - Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação. - Google Patents

Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.

Info

Publication number
BR9712023A
BR9712023A BR9712023-5A BR9712023A BR9712023A BR 9712023 A BR9712023 A BR 9712023A BR 9712023 A BR9712023 A BR 9712023A BR 9712023 A BR9712023 A BR 9712023A
Authority
BR
Brazil
Prior art keywords
processes
preparation
amino acids
compounds
drugs containing
Prior art date
Application number
BR9712023-5A
Other languages
English (en)
Inventor
Klaus Rudolf
Wolfhard Engel
Wolfgang Eberlein
Helmut Pieper
Henri Doods
Gerhard Hallermayer
Michael Entzeroth
Wolfgang Wienen
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19636623A external-priority patent/DE19636623A1/de
Priority claimed from DE19720011A external-priority patent/DE19720011A1/de
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of BR9712023A publication Critical patent/BR9712023A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)

Abstract

Patente de Invenção: <B>"AMINOáCIDOS DERIVADOS, MEDICAMENTOS CONTENDO ESSES COMPOSTOS E PROCESSOS PARA A SUA PREPARAçãO"<D>. A presente invenção refere-se a aminoácidos variados da fórmula geral (I), na qual A, Z, X, n, m, R, R^ 2^, R^ 3^, R^ 4^ e R^ 11^ são definidos tal como nas reivindicações 1 até 5, seus tautómeros, seus diastereómeros, seus enantiómeros, suas misturas e seus sais, especialmente seus sais toleráveis fisiologicamente com ácidos ou bases inorgânicos ou orgânicos, medicamentos contendo testes compostos, seu emprego e processos para a sua preparação, bem como seu emprego para a produção e purificação de anticorpos e como compostos marcados em ensaios RIA e ELISA e como agentes auxiliares diagnósticos ou analíticos na investigação neurotransmissora.
BR9712023-5A 1996-09-10 1997-09-08 Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação. BR9712023A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19636623A DE19636623A1 (de) 1996-09-10 1996-09-10 Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19720011A DE19720011A1 (de) 1997-05-14 1997-05-14 Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Hetstellung
PCT/EP1997/004862 WO1998011128A1 (de) 1996-09-10 1997-09-08 Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
BR9712023A true BR9712023A (pt) 1999-08-31

Family

ID=26029200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712023-5A BR9712023A (pt) 1996-09-10 1997-09-08 Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.

Country Status (33)

Country Link
US (2) US6344449B1 (pt)
EP (2) EP1440976B1 (pt)
JP (2) JP3483893B2 (pt)
CN (1) CN1129605C (pt)
AR (1) AR009742A1 (pt)
AT (2) ATE402187T1 (pt)
AU (1) AU721035C (pt)
BG (1) BG64214B1 (pt)
BR (1) BR9712023A (pt)
CA (1) CA2262818A1 (pt)
CO (1) CO4910127A1 (pt)
CZ (1) CZ82399A3 (pt)
DE (2) DE59711622D1 (pt)
DK (1) DK0927192T3 (pt)
EA (1) EA004037B1 (pt)
EE (1) EE04375B1 (pt)
ES (2) ES2221691T3 (pt)
HK (1) HK1021192A1 (pt)
HR (1) HRP970481B1 (pt)
ID (1) ID21045A (pt)
IL (1) IL128118A0 (pt)
MY (1) MY140677A (pt)
NO (1) NO991130L (pt)
NZ (1) NZ334543A (pt)
PE (1) PE109698A1 (pt)
PT (1) PT927192E (pt)
RS (1) RS49791B (pt)
SA (1) SA97180668B1 (pt)
SK (1) SK285631B6 (pt)
TR (1) TR199900537T2 (pt)
TW (2) TW498076B (pt)
UY (1) UY24704A1 (pt)
WO (1) WO1998011128A1 (pt)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
EP1117662A1 (en) 1998-09-30 2001-07-25 Merck Sharp &amp; Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6387932B1 (en) 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
RU2002111660A (ru) 1999-11-04 2003-11-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Непептидные замещенные бензотиазепины в качестве антагонистов вазопрессина
DE19963868A1 (de) 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2397981C (en) 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
EP1372615B1 (en) * 2001-03-01 2013-04-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
PT1379246E (pt) * 2001-04-18 2009-01-14 Euro Celtique Sa Análogos de nociceptina
BR0210733A (pt) 2001-07-02 2004-07-20 Astrazeneca Ab Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
WO2003057698A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
AU2003237255B8 (en) * 2002-06-05 2010-01-07 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004000808A2 (en) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
JP2006505531A (ja) * 2002-09-11 2006-02-16 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペラジン尿素誘導体
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR101095939B1 (ko) 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US20050042180A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005047251A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
BRPI0416817A (pt) * 2003-11-20 2007-03-06 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
BR0318637A (pt) 2003-12-05 2007-02-13 Bristol Myers Squibb Co antagonistas de receptores de peptìdios relacionados com o gene de calcitonina
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
EA010488B1 (ru) * 2003-12-05 2008-10-30 Янссен Фармацевтика Н.В. 6-замещённые 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли (адф-рибоза) полимеразы
DE102004006893A1 (de) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
US20050192230A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim International Gambh Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018796A1 (de) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050282857A1 (en) * 2004-04-15 2005-12-22 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7547694B2 (en) * 2004-04-15 2009-06-16 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) * 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2569824C (en) * 2004-06-30 2013-03-19 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2006003148A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as parp inhibitors
EP1771422B1 (en) 2004-06-30 2011-02-16 Janssen Pharmaceutica NV Quinazolinone derivatives as parp inhibitors
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
SG157378A1 (en) 2004-09-27 2009-12-29 Acadia Pharm Inc Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
RU2008105987A (ru) 2005-07-21 2009-08-27 Астразенека Аб (Se) Новые пиперидиновые производные
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DE102005042828A1 (de) * 2005-09-09 2007-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGPR-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005050892A1 (de) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
SI2380592T1 (en) 2005-11-14 2018-06-29 Teva Pharmaceuticals International Gmbh The antibody to the calcitonin-related peptide antagonist
WO2007061677A2 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
DK2134330T3 (da) 2007-03-19 2013-08-05 Acadia Pharm Inc Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
JP5745861B2 (ja) 2008-03-04 2015-07-08 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 炎症性疼痛を治療する方法
EP2271626B1 (en) 2008-03-27 2014-11-26 Janssen Pharmaceutica, N.V. Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
EP2260026B1 (en) 2008-03-27 2011-06-22 Janssen Pharmaceutica, N.V. Quinazolinone derivatives as tubulin polymerization inhibitors
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP3165236B1 (en) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
HUE044062T2 (hu) 2011-05-20 2019-09-30 Alderbio Holdings Llc Anti-CGRP készítmények és alkalmazásuk
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
BR112013029959A8 (pt) 2011-05-20 2021-09-08 Alderbio Holdings Llc Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante
JP5988087B2 (ja) * 2012-06-07 2016-09-07 Dic株式会社 化合物の製造方法
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PE20220337A1 (es) 2014-03-21 2022-03-14 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2024100171A1 (en) 2022-11-11 2024-05-16 Boehringer Ingelheim International Gmbh Olcegepant for treating sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3680578D1 (de) * 1985-04-16 1991-09-05 Suntory Ltd Dipeptid-derivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und ihre anwendung.
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
AU587691B2 (en) * 1987-03-30 1989-08-24 Shosuke Okamoto Phenylalanine derivative and proteinase inhibitor
EP0284632A1 (en) * 1987-03-30 1988-10-05 Shosuke Okamoto Phenylalanine derivative and proteinase inhibitor
US5153226A (en) * 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
WO1993025574A1 (en) * 1992-06-12 1993-12-23 Pfizer Inc. Inhibitors of angiotensin i chymase(s) including human heart chymase
EP0706999A1 (en) * 1993-06-30 1996-04-17 Sumitomo Pharmaceuticals Company, Limited Novel dipiperidine derivative
DE69433747D1 (de) * 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
ATE266673T1 (de) 2004-05-15
AU721035C (en) 2004-09-02
EP1440976B1 (de) 2008-07-23
YU37297A (pt) 2002-08-12
NO991130L (no) 1999-05-05
BG64214B1 (bg) 2004-05-31
CN1129605C (zh) 2003-12-03
TW477792B (en) 2002-03-01
US6344449B1 (en) 2002-02-05
AU721035B2 (en) 2000-06-22
UY24704A1 (es) 2000-09-29
BG103250A (en) 2000-05-31
HRP970481B1 (en) 2003-10-31
PE109698A1 (es) 1999-02-01
HRP970481A2 (en) 1998-08-31
SK285631B6 (sk) 2007-05-03
NZ334543A (en) 2000-06-23
EP0927192B1 (de) 2004-05-12
CA2262818A1 (en) 1998-03-19
JP2003300959A (ja) 2003-10-21
CN1230196A (zh) 1999-09-29
ID21045A (id) 1999-04-08
EE04375B1 (et) 2004-10-15
EE9900115A (et) 1999-10-15
JP2000505100A (ja) 2000-04-25
EP1440976A1 (de) 2004-07-28
ES2314305T3 (es) 2009-03-16
EA199900278A1 (ru) 1999-10-28
CZ82399A3 (cs) 1999-06-16
NO991130D0 (no) 1999-03-09
DK0927192T3 (da) 2004-09-13
ATE402187T1 (de) 2008-08-15
RS49791B (sr) 2008-06-05
TW498076B (en) 2002-08-11
TR199900537T2 (xx) 1999-07-21
PT927192E (pt) 2004-09-30
DE59712953D1 (de) 2008-09-04
ES2221691T3 (es) 2005-01-01
DE59711622D1 (de) 2004-06-17
IL128118A0 (en) 1999-11-30
WO1998011128A1 (de) 1998-03-19
HK1021192A1 (en) 2000-06-02
SK29799A3 (en) 2000-03-13
AR009742A1 (es) 2000-05-03
MY140677A (en) 2010-01-15
SA97180668B1 (ar) 2006-08-14
EP0927192A1 (de) 1999-07-07
US20010036946A1 (en) 2001-11-01
EA004037B1 (ru) 2003-12-25
JP3483893B2 (ja) 2004-01-06
CO4910127A1 (es) 2000-04-24
AU4119697A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
BR9712023A (pt) Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
UY26057A1 (es) Amidas de aminoacidos modificadas, medicamentos que contienen estos compuestos y procedimiento para su preparacion
BR9807843A (pt) Heterociclos bicìclicos dissubstituìdos, sua preparação e seu emprego como medicamentos
BR9812944A (pt) Inibidores bicìclicos da cinase
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0110521A (pt) Carbamatos azabicìclicos e seu uso como agonistas de receptores de alfa-7 acetilcolina nicotìnico
BR9808513A (pt) Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico.
BRPI0314325B8 (pt) derivados de aza-bicicloalquila, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BR9916678A (pt) Inibidores de trombina
DK0624596T3 (da) Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler
BR0015056A (pt) Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR0213380A (pt) Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes
EA200501061A1 (ru) N-(1-бензил-2-оксо-2-(1-пиперазинил)этил)-1-пиперидинкарбоксамидные производные и родственные соединения в качестве cgrp-антагонистов для лечения головных болей
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
BR0310077A (pt) Novos compostos e sua utilização
BR0009411A (pt) Composto de anilina substituìda, e, processo para a preparação e uso de compostos
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
BR9802804A (pt) Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos.
BR9909739A (pt) Benzotiadiazóis e derivados
BR9708233A (pt) Processo para sìntese de um composto e composto.
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
BR9712707A (pt) Derivados de ácido 4-bifenil-4-hidroxibutìrico substituìdo com inibidores de metaloprotease de matriz
BR0012757A (pt) Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas
BR9603179A (pt) Guanididas de ácido cinâmico substituìdas, processo para sua preparação, sua aplicação como medicamento ou diagnóstico, bem como medicamento que as contém

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements